Review top news and interview highlights from the week ending August 4, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Four years after submitting its initial BLA for remestemcel-L for steroid-refractory acute graft versus host disease, Mesoblast has encountered another hurdle toward possible approval.
The clinicians from MD Anderson Cancer Center and Washington University – St. Louis shared messages on sarcoma awareness.
The gene-edited cell therapy OTL-200 was approved in Europe in 2020.
The assistant professor at MD Anderson Cancer Center discussed progress of the phase 1/2 trial being conducted at the center.
The initiation of dosing the second cohort in Ultragenyx’s study was recommended by the Data Safety Monitoring Board after a review of safety results from the trial’s first cohort.